Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
– IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end…
– IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end…
Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”),…
–Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28…
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June…
Initial A4100 code being deployed and application for specific HCPCS product code to be submitted…
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sample Fourth…
TORONTO, June 22, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden…
– These results are the first reported demonstration of rapid and robust treatment changes in…
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:…
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;…
–Cash runway extended late into calendar Q2 2023 –Tumor control achieved following MDNA11 treatment in…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc….
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the…
CHATHAM, N.J., June 22, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
ACT-AD ERP P300 Latency post hoc analysis: mITT population, Wilcoxon analysis ACT-AD ERP P300 Latency…
Financing from new and existing investors will support continued development of a novel treatment for…